PT  - JOURNAL ARTICLE
AU  - M. Markman
TI  - What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
AID  - 10.1111/j.1525-1438.2007.01103.x
DP  - 2008 Feb 01
TA  - International Journal of Gynecologic Cancer
PG  - 36--39
VI  - 18
IP  - Suppl 1
4099  - http://ijgc.bmj.com/content/18/Suppl_1/36.short
4100  - http://ijgc.bmj.com/content/18/Suppl_1/36.full
SO  - Int J Gynecol Cancer2008 Feb 01; 18
AB  - Three well-designed and conducted randomized phase 3 trials have revealed that the intraperitoneal administration of cisplatin-based chemotherapy as primary treatment of small-volume residual advanced ovarian cancer improves both progression-free and overall survivals compared to an all intravenous cisplatin-based regimen. Based on very reasonable extrapolations from existing evidence-based data, a number of possible “options” can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting